“Approved” is incomplete unless the statement identifies the product, country and intended use. Menotropins provide a useful example because official product information does not use identical indication wording everywhere.
The Canadian MENOPUR monograph dated March 2026 describes an assisted-reproduction indication involving follicular development. The UK Menopur 75 IU information also includes selected male hypogonadotropic hypogonadism use with hCG. These are statements about named finished medicines in their respective jurisdictions.
Avoid two shortcuts
The first shortcut is assuming that one country's label determines every country's rules. It does not. The second is assuming that an approved medicine containing a related hormone establishes approval for any research-labeled product using that hormone name. It does not do that either.
This distinction is not an argument about whether a clinician may ever consider an off-label use. That is a separate medical and regulatory question. An educational article should not imply that a label covers a use it does not list, nor imply that all uses outside one label are globally prohibited.
When reading a claim, look for a complete sentence: which medicine, in which country, for which condition? If one element is missing, the reader cannot tell what evidence or regulatory status is actually being invoked.
For a treatment discussion, the responsible clinician and pharmacist can identify the local authorized product and explain whether the intended use is within its labeling. For a research catalog, the correct statement is much narrower: a compound-family page can summarize literature without claiming finished-product approval.
This article does not provide legal advice or an exhaustive worldwide approval inventory. It highlights a factual reporting requirement. Keeping jurisdiction and product identity explicit prevents a legitimate medicine record from being used as a blanket endorsement of unrelated inventory or an unspecified clinical purpose.